Skip to main content

Five-minute Q & A: Data & analytics for planning

Computer with graphs and analytics displayed. Notepad and phone sit next to computer.

New trends and change agents are increasingly challenging health systems’ volume and revenue growth. To compete and stay relevant, they must take a more balanced approach to their near-, mid-and long-term growth.

DataGen and Sg2 recently joined forces to host Optimizing strategic planning for revenue growth: DataGen and Sg2 resources. This webinar featured customers' experiences using Sg2's suite of analytical tools and how, when partnered with DataGen's customized customer service and training, these tools helped their organization optimize its strategic planning for enhanced revenue growth. 

We broke down five common questions asked during the session.

1.       What disruptors are you keeping an eye on? 

  • We are keeping an eye on four major disruptors: Retail clinics, big tech/digital, VC-backed medical groups and payers as providers. 

2.       What downstream effects have these disruptors had on inpatient volumes? 

  • Nationally, IP utilization has remained well below pre-pandemic levels through Q2 2022. Through Sg2’s partnership with Strata Decision Technology, we compared adult quarterly volumes from 2019 vs. 2020-2022. Across the country, there is a decline of 10% when you include COVID-19 diagnosis and 14% when you exclude COVID-19 diagnosis. 

3.       What downstream effects have these disruptors had on outpatient volumes? 

  • Outpatient volume demonstrates recovery and growth beyond pre-pandemic levels. According to Strata Decision Technology, the adult quarterly volumes, including COVID-19 from 2019 vs. 2020-2022, revealed OP, OP surgery and E&M are all up between 4% and 5%, while ED visits are flat.  

4.       What are some key 2022 forecast considerations? 

  • Endemic COVID-19 
  • Rising patient acuity  
  • Shift to OP slowing 
  • Expanded care at home capabilities 
  • Record MA enrollment 

5.       What does today’s winning growth portfolio look like? 

  • Near-term: Drive an optimal patient mix through the existing footprint. 
  • Mid-term: Increase revenue and margin capture for patients you serve. 
  • Long-term: Evolve and expand the footprint to win more patients. 
Struggling to get a comprehensive view of your market, competitive position and growth opportunities to guide your strategic planning? Check out how DataGen's partnership with Sg2 can help.


Popular posts from this blog

BPCI Advanced – take advantage of the model extension now

The Bundled Payment for Care Improvement (BPCI) Advanced Model is now open for applications until May 31, 2023. This model provides a unique opportunity to acute care hospitals and physician group practices who are looking to: evaluate their bundle performance; rejoin if they have previously dropped out due to being under a convener; or take advantage of the changes to the model. With a small window to sign the participation agreement, you’ll need experts to process data quickly and accurately for evaluation. BPCI Advanced Program Details The Centers for Medicare & Medicaid Services (CMS) announced in October 2022 that this program will extend from January 2024 to December 2025. Data used for evaluation will be taken from the baseline period between October 2018 and September 2022. A participation agreement will be sent out in September 2023 and needs to be signed by October 2023 in order to participate. Those who apply before the May 31 deadline will benefit

BPCI Advanced Model Extension

CMS recently made several major announcements about the Bundled Payments for Care Improvement Advanced Model.  The model, which was due to expire at the end of 2023 (Model Year 6), will be extended for an additional two years through Dec. 31, 2025.  New applications will be accepted in 2023 for the two-year extension. Participants still active in Model Year 6 can continue without reapplying by signing an amended and restated participation agreement for Model Year 7.  New methodological changes will be implemented for Model Year 6, which starts on Jan. 1, 2023. Methodological changes include that: the CMS Discount Factor for medical clinical episodes will be reduced from 3% to 2%;  the Peer Group Trend Factor Adjustment cap for all clinical episodes will be reduced from 10% to 5%; the Major Joint Replacement of the Upper Extremity clinical episode category will become a multi-setting episode category by allowing episodes to be triggered when the procedure is performed in the hospital ou

You’ve been accepted to the Enhancing Oncology Model. Now what?

The Centers for Medicare and Medicaid Services Innovation Center recently announced approved applicants for the new Enhancing Oncology Model. If your facility has been selected by CMS, are you still weighing your options during the current baseline evaluation period?  Two deciding factors may include the program data that CMS provides and whether EOM is enough of an improvement over the prior Oncology Care Model to make your investment worthwhile. Another factor to consider: Will you have the resources in place to conduct a baseline evaluation before EOM’s program start on July 1, 2023? How EOM differs from OCM EOM aims to improve the coordination of oncology care, drive practice transformation and reduce Medicare fee-for-service spending through episode-based payment. It includes three major updates: Fewer cancer types. Compared with OCM’s 21, EOM will be limited to seven common cancer types: breast, prostate, lung, small intestine/colorectal, multiple myeloma, lymphoma and chronic le